Group 1 - The core business of Yingkang Life includes medical devices and medical services, with medical services accounting for 77.47% of revenue and medical devices 22.53% [2] - As of December 19, the number of shareholders of Yingkang Life is 20,100, a decrease of 0.14% from the previous period, with an average of 31,929 circulating shares per person, an increase of 0.14% [2] - For the period from January to September 2025, Yingkang Life achieved operating revenue of 1.358 billion yuan, a year-on-year increase of 10.59%, and a net profit attributable to shareholders of 86.839 million yuan, a year-on-year increase of 5.20% [2] Group 2 - On December 29, Yingkang Life's stock price fell by 1.39%, with a trading volume of 54.3424 million yuan [1] - The financing buy-in amount on December 29 was 8.3047 million yuan, while the financing repayment was 9.973 million yuan, resulting in a net financing buy-in of -1.6683 million yuan [1] - The total balance of margin trading for Yingkang Life as of December 29 is 234 million yuan, with the financing balance accounting for 3.66% of the circulating market value, indicating a high level compared to the past year [1]

场的良性互动机制。 盈康生命此次获奖，是对其IR团队专业能力与系统化投资者关系管理体系的权威肯定。作为聚焦医疗健康领域的上市企业，盈康生命始终将投资者关系管理 视为连接企业与资本市场的重要桥梁，依托专业IR团队构建了全方位、多层次的投资者沟通体系。在信息披露方面，公司严格遵循监管要求，确保信息披露 的真实、准确、完整、及时与公平，为投资者全面了解公司经营状况与发展战略提供清晰指引，有效稳定了市场预期。 12月26日，以"新开局、新动能、新征程"为主题的"启航·2025金融峰会"在北京圆满举办，大会由金融界主办，汇聚监管部门、行业协会、金融机构、上市 公司、媒体等数百位相关领导和重磅嘉宾。会上，第十四届金融界"金智奖"年度评选结果重磅揭晓，盈康生命荣获"杰出投资者关系（IR）团队奖"。 "金智奖"旨在树立高质量发展标杆，引导上市公司聚焦主业、持续创新、践行社会责任，推动资本向优质企业集聚。本届评选中，金融界上市公司研究院紧 密契合"十五五"规划建议中"提升上市公司质量"的要求，将高质量发展内核分解为社会责任、实业贡献、投资回报、成长前景、创新效率、杰出品牌六大维 度，以企业财务数据和公开信息为基础建立量化分析模 ...

Group 1 - The high-pressure oxygen chamber concept declined by 0.92%, ranking among the top declines in the concept sector, with companies like Innovation Medical, Aoyang Health, and Yinkang Life experiencing significant drops [1] - Among the concept stocks, Jinling Pharmaceutical, Tiedao Heavy Industry, and Hangyang Co. saw increases of 2.93%, 0.77%, and 0.26% respectively [1] - The top-performing concept sectors today included Hainan Free Trade Zone with a rise of 4.32%, and various metal sectors such as zinc and lead, which increased by 3.61% and 3.30% respectively [1] Group 2 - The high-pressure oxygen chamber concept experienced a net outflow of 199 million yuan, with six stocks seeing significant outflows, led by Innovation Medical with a net outflow of 132 million yuan [1] - Other companies with notable net outflows included Hangyang Co. and Yinkang Life, with outflows of 39.31 million yuan and 12.35 million yuan respectively [1] - Conversely, Aoyang Health, Jinling Pharmaceutical, and Dahu Co. were among the stocks with net inflows, receiving 2.49 million yuan, 2.04 million yuan, and 0.47 million yuan respectively [1]

每经AI快讯，12月23日，盈康生命（300143）在互动平台表示，公司控股股东海尔集团已与蚂蚁集团 签署了全面战略合作协议。作为海尔集团在大健康领域的核心生态平台，公司正积极把握此次合作机 遇，相关协同已在业务层面展开。近期，公司联合蚂蚁健康等生态伙伴，共同启动了AI肿瘤全周期管 理生态平台，旨在通过AI技术为肿瘤用户提供覆盖院前、院中、院后的全病程管理服务。双方的合作 方向主要包括：共同探索构建肿瘤防治生态体系、智慧医院解决方案、家庭医疗软硬件一体化方案以及 高端医疗商保支付等创新模式。目前，公司与蚂蚁集团的相关战略协同尚处于框架协议签署后的初期推 进与具体项目落地阶段，对公司短期业绩尚未产生重大影响。 ...

Core Insights - The core focus of the news is the launch of the AI-driven Tumor Full-Cycle Management Intelligent System by Yingkang Life Technology Co., Ltd., aimed at transforming cancer care through technology and collaboration with various partners [1][3]. Company Developments - Yingkang Life has officially released a strategic product, the Tumor Full-Cycle Management Intelligent System, during the AI Tumor Full-Cycle Health Management Development Forum [1]. - The intelligent system aims to provide each cancer patient with a dedicated AI personal doctor, marking a significant shift from a comprehensive medical group to a technology-driven health solution provider [3]. - The system integrates five core functionalities covering early screening, diagnosis, treatment, rehabilitation, and ecological linkage, utilizing an "online + offline" model to address the entire patient journey [3]. Industry Context - In 2022, approximately 4.8 million new cancer cases were reported in China, accounting for 24% of the global total, highlighting the urgent need for continuous cancer care due to an aging population [4]. - Traditional medical services face challenges such as inefficiencies in hospital visits and difficulties in interpreting medical reports, which the new intelligent system aims to resolve [4]. - The industry consensus is shifting towards a full-cycle systemic paradigm in cancer treatment, moving away from fragmented hospital-centric models [5]. Competitive Advantages - Yingkang Life possesses a unique competitive edge through a combination of resources, technology, and service capabilities, which are difficult for competitors to replicate [6]. - The company operates 11 hospitals and care institutions, creating a comprehensive regional medical center and collaborative network [6]. - The integration of AI and digital strategies has positioned Yingkang Life to leverage extensive real-world data from nearly 200,000 cancer patients annually, enhancing the training of medical AI [6][7]. Technological Innovations - Yingkang Life has initiated a digital transformation strategy, achieving interconnectivity among core systems and establishing a "data lake" for enhanced data utilization [7]. - The company is set to enter the "AI Application 3.0 phase" by early 2025, utilizing advanced AI models to improve healthcare delivery [7]. - The intelligent system is designed to provide personalized and empathetic healthcare services, addressing patient needs effectively [8]. Ecosystem Collaboration - The forum featured contributions from partners like United Imaging Healthcare, Ant Health, and Huimei Technology, emphasizing collaborative efforts in advancing AI in healthcare [9]. - Huimei Technology has developed AI solutions that have been implemented in over 1,200 hospitals, focusing on critical clinical processes in oncology [9]. - Ant Health aims to enhance industry collaboration and provide accessible AI health services, aligning with Yingkang Life's vision for a comprehensive health ecosystem [9]. Future Outlook - The Tumor Health Management Intelligent System platform is expected to be fully operational by 2026, with plans to cover one million cancer patients over the next 3-5 years [10]. - The new strategy is anticipated to lead to a valuation restructuring in the capital market, positioning Yingkang Life as a growth-oriented and scarce investment opportunity [10]. - The "online + offline" integration model is expected to enhance patient satisfaction and operational efficiency, driving revenue growth and long-term sustainability for the company [10].

证券日报网讯 12月23日，盈康生命在互动平台回答投资者提问时表示，截至2025年12月19日，公司股 东总数为20087户。 （文章来源：证券日报） ...

AI肿瘤全周期健康管理生态平台启动） 本报记者 刘钊 12月19日，盈康生命科技股份有限公司（以下简称"盈康生命"）在北京举办"AI肿瘤全周期健康管理发 展论坛"。论坛聚焦人工智能赋能肿瘤防治体系变革，来自政策研究、临床医学、科技企业及产业投资 等多领域的专家学者与生态伙伴，共同探讨AI驱动下肿瘤防控新模式的构建。 盈康生命董事兼总经理马安捷称，"公司使命将变成以科技为驱动，为用户提供全场景、全周期的整合 式的健康管理服务。我们将围绕着肿瘤、血液、居家等场景，在医疗服务和医疗器械双轮驱动的基础 上，以科技创新为底座，构建一个AI驱动下的健康解决方案平台"。有业内人士表示，此举将为公司发 展注入全新动能，且可能颠覆传统医疗服务行业生态。 （盈康生命 与传统的互联网医院模式和线下医院的数字化升级不同，盈康生命肿瘤全周期健康管理智能体真正实现 了线上线下的融合，形成了肿瘤全周期健康管理的新业态。 据了解，盈康生命旗下医院每年服务近20万肿瘤患者。目前，我国肿瘤防治事业面临的系统性挑战，同 时叠加人口老龄化趋势，社会对肿瘤长期、连续照护的需求日益迫切。因而，突破传统以医院为中心 的"片段化"诊疗模式，构建覆盖预防、诊 ...

12月19日，盈康生命科技股份有限公司在北京举办"AI肿瘤全周期健康管理发展论坛"。论坛聚焦人工智能赋能肿瘤防治体系变革，来自政策研究、临 床医学、科技企业及产业投资等多领域的专家学者与生态伙伴，共同探讨AI驱动下肿瘤防控新模式的构建。 与传统的互联网医院模式和线下医院的数字化升级不同，盈康生命肿瘤全周期健康管理智能体真正实现了线上线下的融合，形成了肿瘤全周期健康管 理的新业态。 据了解，盈康生命旗下医院每年服务近20万肿瘤患者。目前，我国肿瘤防治事业面临的系统性挑战，同时叠加人口老龄化趋势，社会对肿瘤长期、连 续照护的需求日益迫切。因而，突破传统以医院为中心的"片段化"诊疗模式，构建覆盖预防、诊断、治疗、康复全周期的系统性新范式已成为行业共 识。 自2025年4月发布AI创新应用平台后，肿瘤健康管理智能体的发布也标志着盈康生命AI战略的再升级，即从AI工具到场景产品的升级。依托该智能 体，盈康生命将于2026年正式对外发布肿瘤垂直领域的APP，未来三到五年预计服务百万计用户量，并围绕患者、医生及药械企业需求开发生态服务 产品，实现生态闭环。 财经频道更多独家策划、专家专栏，免费查阅>>责任编辑：栎树 （盈康 ...

Core Viewpoint - The company is focusing on differentiated development in its medical services sector, aiming to enhance its service capabilities and meet diverse market demands through a multi-layered approach [3][4][5] Group 1: Comprehensive Medical Services - The company is expanding consumer health products and personalized services, transitioning from traditional disease treatment to health management that covers the entire user lifecycle [3][4] - In terms of product offerings, the company is solidifying its full-process service capabilities in core specialties like oncology while actively developing new areas such as chronic disease management, precise anti-aging, scientific weight loss, psychological intervention, and traditional Chinese medicine [3][4] - The company is continuously refining a differentiated service system based on high-quality therapeutic effects to systematically enhance its comprehensive service capabilities [3][4] Group 2: Elderly Care Services - The company is building a collaborative health and wellness service capability centered around the "silver economy," focusing on the needs of severe rehabilitation and elderly care [3][4] - Utilizing its medical institutions' professional resources, the company is developing capabilities to meet rehabilitation and nursing demands while exploring a light-asset operation model [3][4] - The company is also leveraging AI capabilities to improve service accessibility, laying the groundwork for future service scenario expansion [3][4] Group 3: Advanced Medical Services - The company is committed to tracking and introducing cutting-edge diagnostic and treatment technologies and service models to continuously enhance diagnostic levels and patient experiences [3][4] - The aim is to meet the evolving and differentiated needs of users through a layered and focused differentiated layout, ultimately constructing a more comprehensive and resilient medical service system [3][4][5]

证券日报网12月19日讯盈康生命（300143）在12月18日回答调研者提问时表示，公司在AI领域的布局 是系统化、分阶段推进的，目前已构建了从数字化基础到智能化应用的完整路径。具体而言，主要经历 了三个关键阶段：第一阶段，是数字化基础建设。此阶段的核心是完成了包括财务、诊疗、医院管理、 支付结算在内的核心系统的统一与互联互通，为实现全流程数据归集与管理奠定了坚实基础。第二阶 段，是实现数字化治理。在统一的数字底座上，公司实现了院内数据的标准化治理，并初步完成了患者 数据的互联互通，为后续的数据价值挖掘创造了条件。第三阶段，公司聚焦肿瘤全病程管理。在此阶 段，公司系统性地推进从算力支撑、算法模型到智能体应用的技术体系建设，致力于构建以AI驱动为 核心的肿瘤全周期健康管理平台。公司目前已经形成了涵盖技术架构与场景验证的体系化能力，这为 AI技术的持续深化与应用扩展奠定了坚实基础。 ...